Oxybutynin Hydrochloride Rosemont Pharmaceuticals (Oxybutynin Hydrochloride)

Oxybutynin Hydrochloride is used in the management of overactive bladder disorders, acting on the urinary tract smooth‑muscle pathway.

• Overactive bladder: improves bladder storage capacity and reduces urgency episodes.
• Urge urinary incontinence: decreases the frequency of involuntary urine loss.
• Detrusor overactivity associated with neurological conditions: lessens uncontrolled bladder contractions.

• Oxybutynin hydrochloride antagonizes muscarinic M3 receptors in the detrusor muscle of the bladder, inhibiting acetylcholine‑mediated contractions. This anticholinergic action relaxes smooth muscle, increasing bladder capacity and reducing involuntary contractions that cause urgency and leakage.

Adverse reactions may vary in frequency and severity.

Common Side Effects

• Dry mouth: reduced salivary flow leading to a feeling of thirst.
• Constipation: slowed gastrointestinal motility.
• Blurred vision: temporary visual disturbances.
• Drowsiness: mild sedation or fatigue.
• Urinary retention: difficulty initiating or maintaining urine flow.

Serious or Rare Side Effects

• Tachycardia: rapid heart rate that may require medical attention.
• Severe allergic reaction: rash, itching, swelling, or difficulty breathing.
• Angle‑closure glaucoma: sudden eye pain and visual loss.
• Hepatic dysfunction: elevated liver enzymes or jaundice.
• Seizures: rare neurologic events requiring urgent care.

When prescribing Oxybutynin Hydrochloride, clinicians should consider patient‑specific factors and follow safety guidelines.

• Assess renal and hepatic function: adjust use if impairment is present.
• Review concomitant anticholinergic load: avoid excessive cumulative effects.
• Monitor for glaucoma risk: patients with narrow‑angle glaucoma should use with caution.
• Advise on constipation management: encourage fluid intake and dietary fiber.
• Counsel on dizziness and fall risk: advise patients to rise slowly.
• Store below 25°C: keep in the original packaging, protect from moisture and direct light.

Oxybutynin Hydrochloride can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Potassium chloride extended‑release: may increase risk of severe gastrointestinal irritation.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): elevate oxy‑butynin plasma levels.

Moderate Interactions (Monitor Closely)

• Other anticholinergic agents: additive dry‑mouth and constipation effects.
• Antihistamines (first‑generation): increased sedation and anticholinergic burden.
• Beta‑blockers: may mask tachycardia caused by oxy‑butynin.
• Digoxin: enhanced risk of cardiac arrhythmias.
• Alcohol: potentiates central nervous system depression.